Novartis Presents New Two-year Data for Cosentyx Showing No Progression in Joint Damage in 84% of Psoriatic Arthritis Patients

Novartis NVS announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment[1]. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American See full press release